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Joint Medicines Regulatory Procedure in the East African Community: Registration Timelines and Way
Forward
J. H. Mashingia 1, S. Maboko 2, P.I. Mbwiiri 3, A. Okello 4, S. I. Ahmada 5, R.Barayandema 6, R. Tulba 7, E.
Byomuhangi 8, Z. Ekeocha 9, S. Byrn 10, K. Clase 11
ABSTRACT

A review of the East African Community (EAC) joint regulatory review process was conducted, registration
timelines analyzed and key milestones, challenges and opportunities documented for the period of July 2015 to
January 2020. A total of 113 applications were submitted for joint scientific review. Among these, 109
applications were assessed, 57 were recommended for marketing authorisation, 52 applications had queries to
applicants and four applications were under review.
A total median approval time for all products ranged from 53 to 102 days. The maximum time taken by a
regulator to review the dossier was 391 days and the minimum time was 44 days. For applicants, the maximum
time to respond to queries was 927 days and the minimum time was nine days.
The total median time for granting marketing authorisation by the National Medicines Regulatory Authorities
(NMRA) decreased from 174 to 39 working days in 2015 and 2019 respectively. However, not all EAC NMRA
has granted marketing authorisation to all 57 products due to non-payment of applicable fees by applicants.
Long regulatory approval timelines were contributed by limited capacity for timely scientific review of dossier by
some NMRA, lack of online portal to share dossiersand assessment reports, delay in responding to queries by
applicants and deficiencies in dossier. The metric tool and register of medical products submitted for joint
scientific review had incomplete data.
Challenges were identified and actions recommended to ensure regional regulatory system optimization,
efficiency, transparency, sustainability and accountability.
Keywords: Registration, assessment, timelines, harmonization, regulatory review, medicinal Products, marketing
authorization
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1. INTRODUCTION
Harmonization of pharmaceutical regulations and
cooperation at regional and continental level
contribute to increase availability of high-quality, safe
and effective medicines in developed and developing
countries (Pierre, 2014). Harmonization of
regulations involves establishing an effective
network of continental regional and national, or
regulatory authorities. The networks facilitate sharing
of scientific knowledge, best practices, skills and
appropriate use of limited resources to avoid
duplication of efforts, reduce cost to pharmaceutical
industry and promote innovation and development of
medicines for unmet medical needs (NdomondoSigondaet al, 2017). The networks are important
structures to build regulatory capacities and
capabilities, trust and confidence between National
Medicines
Regulatory
Authorities
(NMRA).
Conceptualization of harmonization of medicines
regulatory frameworks in the East African
Community started in 2009 during a continental
meeting of Drug Regulatory Authorities (DRA) that
was convened to discuss issues surrounding
harmonization of drug regulatory requirements and
systems in the African continent. The meeting was
organized by African Union New Partnership for
African’s Development (AU-NEPAD Agency), under
auspices of African Union Pan African Parliament
(PAP), with support from the Bill and Melinda Gates
Foundation (BMGF). The East African Community
(EAC), with the main mandate of facilitating
integration and harmonization of legal, policy and
regulatory instruments, was better placed to
coordinate the initiative to address regulatory and
technical barriers on access to medicines, vaccines
and health technologies. EAC is a regional intergovernmental organization of the six Partner States

namely: The Republic of Burundi, the Republic of
Kenya, the Republic of Uganda, the Republic of
Rwanda, Republic of South Sudan and United
Republic of Tanzania (www.eac.int). The six Partner
States have a unique framework for regional
cooperation, and integration in the health sector, as
stipulated in the EAC Treaty, Chapter 21, Article 118
(EAC, 2000). The East African Community
Medicines Regulatory Harmonization (EAC-MRH)
programme was launched by the EAC Council of
Ministers on 30th March 2012, with the goal of
establishing a standardized and harmonized
regulatory systems to ensure safe, efficacious,
quality and effective medicines for treatment of
priority diseases (S. EAC, 2010). The programme is
implemented by seven National Medicines
Regulatory Authorities (NMRA) and EAC Secretariat
is the coordinating body. The implementing agencies
include the Department of Pharmaceuticals and
Medical Laboratories (DPML) of Burundi, Pharmacy
and Poisons Board (PPB) of Kenya, National Drug
Authority (NDA) of Uganda, Drug and Food Control
Authority (DFCA) of South Sudan, Rwanda Food and
Drugs Authority (Rwanda FDA), Tanzania Medicines
and Medical Devices Authority (TMDA) and Zanzibar
Food and Drugs Agency (ZFDA) of the United
Republic of Tanzania. In addition, the African
Medicines Regulatory Harmonization Partners
(AMRH), namely the World Health Organization
(WHO), African Union Development Agency (AUDA),
formerly known as African Union New Partnership for
Africa’s Development (AU-NEPAD), the Bill and
Melinda Gates Foundation (BMGF), the World Bank
(WB), United Kingdom Department for International
Development (UK-DFID), Swiss Development
Corporation (SDC) and United States Agency for
International Development (USAID) provided support
to the initiative.

Technical partners include WHO and Swiss Agency
for Therapeutic Products, while African Union
Development Agency (AUDA) plays a high level
advocacy
role
on
medicines
regulation
harmonization in the continent working with Regional
Economic Communities (REC) such as EAC,
Southern African Development Community (SADC)
and Economic Community of West African States
(ECOWAS), Partners (BMGF, UK-DFID, WB, USAID
and SDC) provide financial resources to AMRH Trust
Fund to support AMRH initiative in different RECs.

b) To implement a common information
management system (IMS) for medicines
registration in each of the EAC Partner
States NMRA which are linked in all Partner
States and EAC Secretariat;

The programme has six objectives:

e) To create a platform for sharing information
on the harmonized medicines registration
system to key stakeholders at the national
and regional level;

a) To implement an agreed common technical
document (CTD) for registration of
medicines in EAC Partner States;

c) To implement a quality management system
in each of the EAC Partner States NMRA;
d) To build regional and national capacity to
implement
medicines
registration
harmonization in the EAC;
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f)

To develop and implement a framework for
mutual recognition based on Chapter 21,
Article 118 of the East African Community
Treaty.

The initial phase of the EAC-MRH programme
(March 2012 - December 2017) focused on:
a) establishment of regional governance
structures to support implementation and
sustain the programme
b) development of harmonized technical
guidelines, procedures and tools for joint
registration (EAC Common Technical
Document-CTD)
and
joint
good
manufacturing practices (GMP) inspections
c) establishment of a quality management
system in all EAC NMRA
d) institutional capacity building on regulatory
sciences
e) high level policy advocacy for establishment
of semi-autonomous National Medicines
Regulatory Authorities (BCG, 2017).
EAC Joint Regulatory Procedure
EAC joint medicines regulatory procedure involves
joint scientific evaluation of safety, efficacy and
quality of medicinal products and joint inspections of
pharmaceutical manufacturing facilities to assess
compliance to Good Manufacturing Practices (GMP)
standards.
The following procedures are undertaken under the
EAC joint regulatory review:
a) Evaluation of medical product dossiers;
b) Joint physical inspections of manufacturing
sites or desk review in line with EAC
Compendium of guidelines for GMP (EAC,
2018);
c) Joint inspections of clinical sites, if
applicable according to the Good Clinical
Practices (GCP);
d) Joint post-marketing surveillance and safety
reporting;

e) Enforcement of joint regulatory decisions by
NMRA.
For the purpose of this study, the focus was on joint
evaluation of medicinal product dossiers, which also
involves joint inspections of pharmaceutical
manufacturing facilities, depending on outcomes of
dossier evaluation. The study narrowed down on
analysis of registration timelines to evaluate if the
process demonstrated efficiency and could be
optimized to ensure predictability, consistency and
accountability. The terms “joint assessment” and
“registration” will be used interchangeably with joint
registration procedure or dossier evaluation.
Submission of Dossier in CTD Format
The EAC joint assessment and registration process
came to fruition in July 2015 after nine medicinal
product dossier applications were lodged for joint
evaluation and registration. The EAC procedure is
highlighted in Figure 1. The procedure begins with
submission of an application to TMDA, the lead
NMRA for Medicines registration (Step) The
medicinal product dossier should be in line with EAC
guidelines on submission of documentation for
registration of human medicinal products for
preparation of marketing authorization application in
the common technical document (CTD) (EAC,
2019a). Screening is conducted by the lead NMRA
(Step 2) and the lead NMRA for GMP will be notified
to verify GMP status and the applicant notified
whether the dossier is accepted or rejected within 14
days. If the dossier is complete, the application will
be assigned to 1st and 2nd assessor, as per EAC
standard operating procedure for joint assessment,
and scheduled for joint assessment. Dossier
assessment will be conducted within three months
following successful screening (Step 3, 3.1 & 4). The
evaluation of additional data will be conducted within
two months of receipt and a maximum of three
rounds of queries is permitted (Step 5, 5.1 & 5.2).
Following successful dossier evaluation and
compliance with Good Manufacturing Practices, the
experts will make recommendations to the EAC
Heads of NMRA and will recommend to the EAC
Secretariat to issue confirmation letter to the
applicant/manufacturer (Step 6 & 7).
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Figure 1. Infographic of EAC Joint Assessment Procedure
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National administrative procedure to grant marketing
authorisation (MA) takes three months from the date
of joint acceptance. The respective EAC Partner
States NMRA will issue a certificate of MA, which
confirms the final registration outcome (Step 8).
Registered products shall be maintained in each
NMRAs list of registered products and EAC
Secretariat (Step 9). The EAC Partner States will then
monitor the safety and quality of the products in line
with the national policies and regulations. In addition,
EAC Compendium of Pharmacovigilance Guidelines
(EAC, 2019b) requires the applicant to ensure safety
of their products they place in the EAC market and in
this regard, the EAC NMRA will jointly monitor safety
of the products registered through the EAC-MRH
scheme using standardized tools and procedures.
According to the EAC joint assessment procedure,
scientific evaluation of dossiers by a regulator should
be carried within 181 working days. The applicant’s
response to queries is 180 working days. Once a
regional positive outcome of the assessment is
issued, alle EACNMRA are required to issue
marketing authorization within 90 working days
following a positive regional recommendation.
EAC Joint
Inspections

Good

Manufacturing

Practices

Initiation of EAC Joint GMP inspection may occur
through three mechanisms:
a) A joint procedure in the framework of multiple
applications for marketing authorization to
more than one NMRA
(joint assessment and registration);
b) An official request from a manufacturer;
c) A joint interest of at least two EAC Partner
States NMRA.
The procedure for joint GMP inspections, as indicated
in Figure 2, requires an applicant to submit an
application including the Site Master File and
applicable fees to the lead NMRA for GMP, National
Drug Authority (NDA), Uganda and other NMRAs, as
per their fee guidance. Scheduling of joint inspections
will be done by the lead NMRA, while the maximum
number of inspectors per site is three, drawn from two
NMRAs. Communication of the inspection dates will
be done within 14 days by the lead NMRA. Site visit
and inspection will be conducted within 30 working
days from the day of scheduling. Communication of
the outcome of inspection will be within 42 working
days from the dates of inspection. Review of
Corrective and Preventive Actions (CAPA) and
responses by the applicant will be completed within
90 working days.
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Figure 2. EAC Joint GMP Inspection Procedure Flow Chart
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The letter, which confirms the final inspection
outcome, will be communicated by the EAC
Secretariat. National approval will be granted within
three months from the date of joint acceptance; and
respective EAC NMRAs will issue a certificate, which
confirms the final inspection outcome. EAC NMRA will
maintain the list of inspected sites and continue to
monitor compliance to EAC GMP standards after
every three years.

To ensure timely availability of quality medicinal
products and effective medicines registration and
marketing authorization, it is important to have
timelines tracking the system to evaluate performance
of the system and ensure compliance to agreed
timelines. The EAC has developed a comprehensive
metric tool to track timelines for joint registration and
joint GMP inspections. The clock stop system is
implemented to monitor the length of the review
process.
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Metric Tools to Track
Assessment Procedure

Timelines

of

Joint

•

The metric tool for joint registration procedure is an
Excel sheet which contains six sections as indicated
below:

•

(i) Section 1: Application Details
This section documents application number,
brand name, generic name, pharmaceutical
form, therapeutic class, type of product,
applicant name, manufacturer, date of
submission of dossier and date of notification
to the EAC expert working group (EWG) for
GMP.
(ii) Section 2: Screening Process (14 days)
This part covers the date of completion of the
screening, date when the outcome of
screening is communicated to applicant, date
of receipt of updated dossier, final outcome
(accepted/rejected)
and
date
of
acceptance/rejection of dossier.
(iii) Section 3: Evaluation Process

•
•

Date additional information is submitted by
applicant (120 days);
Date when first assessment of query
response is completed by first assessor (14
days);
Date when second assessment of query
response is completed by second assessor
(seven days);
Date when query response assessment
report is discussed and finalized at EAC level
(seven days).

Fourth Cycle of Evaluation
(Third and Final Round of Queries)
• Date additional information is submitted by
applicant (120 days);
•

Date when first assessment of query
response completed by first assessor (14
days);

•

Date when second assessment of query
response completed by second assessor
(seven days);

(iv) Section 4: Final Recommendations

First Cycle of Evaluation

This section captures information on whether the
product has been accepted or rejected. It also
covers:

•

Date the first assessment is completed (21
days);

•

Date second assessment completed (14
days);

•

Date when
reached;

recommendations

are

•

Date the assessment report is discussed and
finalized (seven days);

•

Date when final recommendations
communicated to applicant.

are

•

Date recommendations are communicated to
applicants (14 days).

Second Cycle of Evaluation
(First Round of Queries)
• Date additional information is submitted by
applicant (180 days);
•

Date first assessment of query response is
completed by first assessor (14 days);

•

Date second assessment of query response
completed by second assessor (seven days);

•

Date when query response assessment
report discussed and finalized at EAC (seven
days);

•

Date
when
recommendation
communicated to applicant (seven days).

Third Cycle of Evaluation
(Second Round of Queries)

is

final

(v) Section 5: NMRAs Implementation of
Regional Recommendations
This section contains the following:
• Date when EAC Secretariat communicates
final recommendations to all EAC NMRA
(14 days);
• Date when the product is granted marketing
authorization (MA) by each individual EAC
NMRA (90 days).
(vi) Section

6:

Post

Approval

Process

The section document time period of
communication made to theEAC expert working
group (EWG) for pharmacovigilance (PV) and
post-market surveillance (PMS) following
approval for marketing authorization., This also
applies for variations and renewals. If the product
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is withdrawn from the market, then it should be
documented in this section.
Metric Tool for EAC Joint GMP Inspections
The metric tool for EAC Joint GMP Inspections is an
Excel sheet which contains five sections as
highlighted
below.
Section 1: Application Details
This section captures information on application
number, name of applicant, site(s) address(es),
contact person on site, category of medicines,
registration status of products and number of
production lines to be inspected.
Section 2: Screening Process
This part covers date of completion of screening (five
days) and course of action (physical inspection/desk
review).

•

Peer-review monthly reviews (14 days);

•

Recommendations
applicant (five days).

•

Date submission of CAPA is done by
applicant (90 days);

•

Date review of CAPA concluded (14 days);

•

Date recommendations are communicated to
applicant (five days);

Clock Stop System for EAC Joint Assessment
The clock watch system for EAC joint assessment and
registration is summarized below:
•

First Cycle of Evaluation
o

This section contains:
Scheduling of inspections (14 days);

•

Date of lead NMRA communicates to
applicant on Schedule of Inspection;

•

Date Lead NMRA communicates to Partner
States on dates of joint inspections;

•

Date the applicant confirms the inspection to
be conducted (30 days);

•

Submission of names of inspectors by EAC
Partner States (seven days).

•

Planning and preparation (30 days);

•

Inspection (five days);

•

Report writing (seven days);

The evaluation process is a step-by-step process and
the metric tool has been designed to document the
time period (working days) of each step using a clock
stop system.
Confidentiality of Manufacturers Data
Confidentiality of shared data is assured by
mechanisms applied by participating parties (EAC
NMRA). Participating NMRA create a written
commitment that “any information and documentation
provided to them by applicants will be treated as
confidential and access to this information will be
allowed only to persons involved in the joint
assessment and registration procedure”. The

Clock Stop 1: The evaluation is
paused (first clock stop) while
the applicant prepares the
responses
to
EWG
for
Medicines
evaluation
and
registration (MER).

•

Second Cycle of Evaluation
o Clock Stop 2: The evaluation is
paused again for applicant to
address outstanding issues.

•

Third Cycle of Evaluation
o

Section 4: Planning and Inspection
This section covers:

to

Section 5: Review of Corrective and Preventive
Action (CAPA)

Section 3: Scheduling
•

communicated

Clock Stop 3: The evaluation is
paused for applicant to provide
clarifications on outstanding
issues.

•

Fourth

Cycle

of

•

Final discussion and
scientific review opinion.

Evaluation
adoption

of

expertsare bound by confidentiality statement and
commitment as specified in Part 5 of the EAC
Compendium of Quality Management System
Technical Documents For Harmonization of
Medicines Regulation in the East Africa Community,
the EAC Code of Conduct for EAC Partner States
NMRA (EAC/TF-MED/QMS/FD/COM/N3R0).
Timelines for EAC Joint Assessment Procedure
The time spent by EAC experts to conduct scientific
evaluation is 181 working days and the time is
interrupted by three clock stops during which the
applicant prepares the answers to questions raised by
an EAC expert working group for medicines
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evaluation and registration (MER). The time for the
applicant to respond to queries is 180 working days
while national administrative procedures to grant
marketing authorisation is 90 working days. The
overall assessment of medicinal products usually
takes approximately a full calendar year (360 days).
Since commencement of joint assessment and
registration procedure in July 2015, a total of 113
applications have been submitted for joint scientific
review. Among these, 109 applications have been
assessed, 57 have been recommended for marketing
authorisation, 52 applications have queries to
applicants and 4 applications are under review.
Studies have been conducted in relation to the East
African
Medicines
Regulatory
Harmonization
Programme (Hiiti et al., 2020; Jane et al., 2020;
Margareth et al., 2020). However, none focused on
analysis of the registration timelines for the EAC joint
evaluation procedure. This study therefore
wasconducted with the following objectives:
(i) To document stages of the EAC joint
regulatory review process;
(ii) To review the metric tool and analyse
registration timelines;
(iii) To identify key milestones, challenges and
opportunities.
Data collection template was developed to enable
structured documentation of all relevant information
extracted from the metric tool (Excel sheet) in a
summarized manner. The template contained
information on application number, pharmaceutical
form, therapeutic class and type of product, date of
submission of application, notification to EWG on
GMP, type of assessment (full or abridged), round of
assessment, date when final report was discussed
and completed, regulators time (working days),
applicant timelines (working days), final outcome
(accepted /rejected) and date when final
recommendation were communicated to the
applicant. Regulators and applicant timelines were
obtained by reviewing data in the metric tool for each
product from the date of submission, date of clock
start/stop and date of approval. Number of days were
counted for each evaluation step, as indicated in the
introduction section of the evaluation steps and
rounds of queries. Timelines for the applicant and
regulator were obtained considering clock start and
stop system and summed up to get the total number
of working days. Appendix 2 summarizes the findings
and registration timelines of each product. Based on
the metric tool and the EAC register of medicinal
products, the 57 medical products
were
recommended for marketing authorisation hence they
formed study sampling frame.

2. METHODS
Information on the total number of applications and
approvals for the period of July 2015 to January 2020
was obtained from the register of medicinal products
submitted for joint evaluation and registration (TMDA,
2015). Review of the metric tools for joint evaluation
procedure and joint GMP inspections was done
(RTO's & Secretariat, 2018a; 2018b). Analysis of
regulatory approval times between July 2015 to
January 2020 for 57 medicinal products
recommended for registration was conducted.
Retrospective
review
of
other
program
documentations, such as guidelines, templates,
standard operating procedures (SOP’s) and reports,
was conducted. Documents were available at EAC
Secretariat and others were obtained from Tanzania
Medicines and Medical Devices Agency (TMDA) and
National Drug Authority (NDA).
Study Hypothesis
•

There is a significant reduction in the
regulatory approval timelines between 2015
and 2020 for EAC joint assessment and
registration procedure;

•

Long regulator timelines are associated with
the type of evaluation process.

Data Collection
Statistical

Analysis

Study data was processed in Microsoft Excel to test
the
hypotheses
and
examine
associationsbetweenvariables.

3.RESULTS AND DISCUSSION
Scientific evaluation of safety, quality and efficacy
data in the dossier was conducted by assessors from
the seven EAC NMRA. Two experts from each EAC
NMRA formed the EAC Expert Working Group (EWG)
for Medicines Evaluation and Registration (MER). The
primary mandate of this network of assessors was to
provide technical guidance in all matters related to
medicinal product registration to the Forum of Heads
of EAC NMRA. This arrangement was adopted by the
EAC Council of Ministers in September 2014, since
there was no regional regulatory body that is
mandated to oversee regulation of medicines in the
EAC region.
As indicated in Figure 1, once a dossier was
submitted and accepted, it was assigned to first and
second assessors. The assessors conducted
evaluation at the national level and shared reports
with other regulators. Then the assessment report
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was reviewed and discussed during face-to-face
meetings with assessors.
A total of 113 applications were submitted for EAC
joint scientific review. Among these, 109 applications
were assessed, 57 were recommended for marketing
authorisation, 52 applications had queries to
applicants and four applications were under review.
The highest number of products recommended for
marketing authorization was in the year 2016 (n=19)

and the lowest number was in 2018 (n = 5) , as
indicated in Appendix 1.

Figure 3. Trend of Regulator and Applicant Timelines for a Period of 2015 to 2019
1000

Working Days

750
500
250
0

2015

2016

2017

2018

2019

Year
Regulator Timelines

There was a significantly long regulatory approval
timeline (1,052 working days) in 2016, as indicated in
Figure 3 above. The main reason was the delay of
manufacturers to respond to queries raised, which
took 927 working days, while the regulator’s time was
125 working days. A similar challenge was observed
by Ahonkhai et al. (2016) in which long regulatory
review period was due to delay to respond to queries
by sponsor. In addition, the quality product dossier
submitted had insufficient data, which led to more
rounds of queries and negatively impact review
period. The EAC assessors had an obligation to
ensure the products submitted for registration met
standards as stipulated in EAC guideline for
registration of human medicinal products. The trend
of timelines for regulators indicated a steady
improvement throughout the years. This was
contrary to the findings by Dansie et al. (2019), which
indicated hesitation of manufacturing companies to
use the EAC joint assessment procedure. The main
reason was due to the length of time to receive the
actual marketing authorization and unexpectedly

Applicant Timelines
higher quality standards than national procedures.
For all 57 products, the longest time taken by a
regulator to review the dossier was 391 days in 2016
and the shortest time was 44 days in 2019. For
manufacturers (applicant), the longest time to
respond to queries was 927 days (2015) and the
shortest time was 9 days in 2018 (Figure 3 &
Appendix 2).
For regulators, the root cause of long review
timelines was mainly due to lack of an integrated
information management system portal to support
timely sharing of dossiers and assessment reports.
In addition, the region had NMRA with different
capacities and capabilities of assessors to conduct
timely scientific reviews of medicinal product
dossiers of different product categories. However,
the EAC-MRH program continued to provide a
greater opportunity for capacity building across the
region to bridge the gap between highly skilled and
less-resourced NMRA.
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Figure 4. Therapeutic Category of Products Submitted for EAC Joint Assessment Procedure
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Therapeutic categories of products submitted for
joint evaluation process for the past five years were
mainly
antineoplastic/biologicals,
antidiabetics,
monoclonal
antibodies,
antimicrobials
and
antihypertensives as indicated in Figure 4. The
scope of products for consideration under the EAC
joint assessment procedure included medicines,
biotherapeutics and biosimilars. The priority was
given to medicines to manage maternal, neonatal
and children’s health conditions, HIV, malaria,
tuberculosis and neurological disorders. In addition,
the EAC Expression of Interest have listed category
of products for management of neglected diseases
such
as
leishmaniasis,
pneumocystosis,
toxoplasmosis, filariasis and strongyloidiasis (EWG
& Registration, 2020). Apart from the listed products,
the EAC routinely conducted mapping of common
applications submitted in at least two EAC Partner
States NMRAs and requested the applicant to
consent to participate in the joint review process.
A joint assessment procedure involved full and
abridged evaluations. An abridged procedure was for
medicinal products already approved by stringent
regulatory authorities and the WHO prequalification
program. For this procedure, the assessors
employed a risk-based approach in the evaluation
process and review of the quality information
summary of the finished pharmaceutical product

600
■ Applicant

900

1200

Timelines

(QIS-SRA) submitted by the applicant. The reviewer
focused on the main aspects of Active
Pharmaceutical Ingredient (API) quality and stability.
For finished pharmaceutical product, the assessor
reviewed
specifications,
labelling
and
the
manufacturing process. For any variations (post
approval changes) to the products, the EAC
guideline on variation to a registered pharmaceutical
product or vaccine would be applicable.
Full evaluation involved review of all data related to
quality, safety and efficacy of the drug product. For
this study, data were analysed according to the type
of evaluation to discover if this variable would have
an impact on regulator timelines and determine
whether the hypothesis was true. As indicated in
Figure 5 below and Table 2 (Appendix 2), for the year
2019, full evaluations of product 040, 041, 042, 043
and 044 took a period of 166, 63, 63 and 85 working
days respectively; while abridged assessment of
product 045, 046, 047, 048 and 049 in the same year
took 222, 222, 222, 222 and 229 working days
respectively. In addition, in the year 2015, abridged
evaluation of product 001, 002, 003 and 004 took 53
working days each, while full evaluations of product
005, 006, and 007 took 125 working days each.
Based on the findings for the year 2015, 2016, 2018
and 2019, there was no correlation between
regulators’ timelines with the type of evaluation.
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Figure 5. Regulator’s Timelines Vs Type of Assessment Method for a Period of 2015 to 2019
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For the year 2019, abridged assessment took longer
than 181 days, as per the standard operating
procedure for joint assessment; while full
assessment was less than 181 days for the five
products mentioned above. For year 2015, both
abridged and full assessment took less than 181
days. For 2017, the type of evaluation was not
documented in the register of medicinal products

submitted for the joint review process as indicated in
Appendix 2. Incomplete data in the metric tool and
other records should be addressed by the
programme implementers so that future studies’
findings can represent the real situation.
During the past 5 years, the total median approval
time (submission through end of assessment) for all
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products ranged from 53 days in 2015 to 102 days in
2019. There was a significant increase in the total
median approval time (476 working days) in 2016, as
indicated in Figure 6. Long median time was
contributed due to the following reasons:
a) the dossier submitted by the applicant did
not
have
bioequivalence
data
to
demonstrate that a generic product
submitted for registration is bioequivalent to
its reference or originator product;
b) the package of products submitted did not
meet EAC Common Technical Document
(CTD) requirements;
c) there was a delay in response to queries by
applicants

d) there was a delay in submission of
assessment reports by assessors
e) stringency of regulators.
Deficiencies in the dossier were also observed by a
study conducted by the WHO prequalification
program (Wondiyfraw et al., 2012).
During the same period (2016), the median time for
an applicant was 187 days while median time for a
regulator was 289 days. The findings further
indicated a decrease in total median time from year
2017 to 2019, as indicated in Figure 6. The median
time for a regulator decreased from 169 days to 102
days and manufacturers ranged from 88 days to zero
days. This showed improvements in the processes
and high commitment by all stakeholders involved in
the joint assessment procedure, which led to

Figure 6. Median Timelines for Regulator and Applicant Per Year
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improved efficiency and effectiveness of the whole
process. Both regulator and applicant were
compliant to the set timelines of 181 and 180 days,
respectively. The results of this study were different
from the study conducted in 2014 to evaluate central

0
2019

Total Median Approval Time

registration procedure by the Gulf Cooperation
Council (Al-Rubaie et al,, 2014). The evaluation of
the Gulf Centralized Procedure indicated an increase
in median approval time from 107 calendar days in
2006 to 265 days in 2010. The increase was due to
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a limited number of meetings by the Gulf Cooperation
Council-Drug Registration (GCC-DR), and a delay of
assessment reports due to a lack of standard
evaluation templates for product assessment, which
lead to an increase in correspondence by GCC-DR
to the sponsor requesting additional information. A
similar study conducted by Andrea et al. (2018) for a
regulatory review process in the South Africa
indicated overall regulatory median approval time
decreased by 14% in 2017 (1411 calendar days)
compared to 2016, despite the 27% increase in the
number of applications. The findings of South Africa
regulatory process further indicated the regulatory
agency had no target for overall approval time of new
active substance applications, no target for key
review milestones and an abridged assessment
procedure was not implemented.
Among the seven NMRAs implementing the EACMRH program, only one (Tanzania Medicines and
Medical Devices Agency) granted marketing
authorisation to all 57 medicinal products
recommended for registration at EAC level.
Pharmacy and Poisons Board of the Republic of
Kenya granted marketing authorisation to 35
medicinal products and National Drug Authority of
Uganda granted marketing authorisation to 25
medicinal products, as indicated in Appendix 3.
Rwanda Food and Drugs Authority (Rwanda-FDA)
granted pre-registration to five antineoplastic drugs
and one antiseptic solution. Among the
antineoplastic drugs, four were approved at EAC
level on 3rd October 2015 and one in September
2016. The antiseptic solution was recommended for
registration at EAC level on 15th December 2017. In
addition, two medicinal products were awaiting
approval by Rwanda FDA which included an
antihypertensive drug and a drug for management of
overactive bladder. Both were recommended for
approval on 7th December 2018.
The Zanzibar Food and Drugs Agency (ZFDA)
granted pre-registration to an antiretroviral drug
which was recommended for approval in January
2018. The other NMRAs of the Republic of Burundi
and Republic of South Sudan had not registered any
medicinal products, as the applicants had not yet
shown interest in placing their products in these
countries’ markets by paying applicable fees. Non-

payment of fees by the applicants was also observed
for other countries (i.e. Uganda, Kenya and Rwanda)
as indicated in Appendix 3.
Once a regional recommendation was issued and
communicated to the applicant, the manufacturer
was required to pay the applicable fees for each of
the respective EAC Partner States NMRA for their
products to be placed in market. Each of the EAC
Partner States have fee guidance and structure
governed by that country’s regulations and
jurisdiction. Appendix 3 highlights the products in
which the applicant had not yet paid fees for their
products to be granted marketing authorisation (MA)
by the remaining six NMRAs. Most of the products
were granted MA by TMDA because it is the Lead
NMRA for the program component of drug evaluation
and registration. In this regard, TMDA received all
applications for joint evaluation procedure and
screened the dossier and distributes to assessors for
evaluation. Since it was the primary point for the joint
assessment procedure, most of the time, the
applicant submitted the dossier as per EAC CTD and
the applicable fee.
In order to encourage applicants to introduce their
products in all EAC Partner States markets, the 19th
EAC Sectoral Council of Minister of Health, held on
1st November 2019, recommended a two year
window period for applicants to apply for marketing
authorization from all EAC NMRA directive
(EAC/SCHealth/19/Directive/050). In this regard, the
applicant had two years to pay the applicable fee in
each NMRA for their products to be placed in the
respective markets. In addition, the Council of
Ministers of Health further introduced a priority
voucher mechanism for applicants who made timely
payment of fees to all Partner States NMRAs
following positive outcome of EAC as per directive
EAC/SCHealth/19/Directive/053. Once a marketing
authorisation was granted by an individual NMRA, it
was valid for five years, as per EAC guideline for
registration of human medicinal products, and the
applicant was able to apply for renewal once the
validity expires using the same guidelines. However,
the applicant needed to specify in the application
form as “renewal” and not “new application.”

Figure 7. Median Timelines for Granting Marketing Authorisation by NMRAs of Kenya, Uganda and United
Republic of Tanzania
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The procedure recommended a period of 90 working
days for each of the NMRA to grant marketing
authorisation following a regional positive outcome
and payment of application fees by the applicant. The
median time for granting marketing authorisation for
three NMRA was analysed using an Excel sheet and
the findings indicated a decrease in total approval
median time from 174 working days in 2015 to 39
working days in 2019. The median time for PPB

2017
Year

2018

Median Time for TMDA

39
34
5
0

2019

Total Median Time

ranged from 0-5 working days, NDA ranged from 150
-0 working days and TMDA ranged from 24- 5
working days (2015 to 2019). The reason for a long
median timeline of approval for NDA was the delay
for the applicant to pay the registration fee based on
national requirements.
For the period of 2019, the median time for PPB was
34 working days, NDA was zero working days and
TMDA was five working days. This showed
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continuous improvements in the processes and high
compliance to agreed timelines for granting
marketing authorisation by NMRA.

Clinical Trial Control Oversight with
adoption of the African Vaccine Regulatory
Forum (AVAREF) guidelines and tools for
domestication in the EAC region.

EAC Joint GMP Inspection
Since commencement of EAC joint GMP inspections
in July 2015, the region conducted (22) joint
inspections of pharmaceutical manufacturing
facilities in Uganda, Bangladesh, India, Palestine,
Kenya, China, Germany, Italy, Belgium, Egypt,
Morocco and Tanzania. Among these, only one joint
inspection was triggered by a dossier application
submitted for joint review. The other inspections
were conducted based on the mapping of common
backlog of applications in all seven NMRA and upon
official request from the manufacturer.

4. CHALLENGES
Despite progress made by the initiative, there were
some challenges identified by the study that should
be addressed to ensure improvement in the system
and optimize the processes to deliver the program
goal and objectives. The challenges observed by this
study
are
related
to:
•

Data Management: The study observed
incomplete data in the register of medicinal
products and the metric tool (registration).
This indicated limited consistency in data
entry to the metric tool when each step is
initiated and finalized at both national and
regional level. The metric tool was not
automated, which hinders accessibility and
timely entry of data by all NMRA and EAC
Secretariat.
Based on
the current
arrangement, the metric tool for registration
was managed by TMDA and GMP metric
tool was managed by NDA.

•

Integrated
Information
Management
System: Lack of regional integrated
information management system (IMS) to
support sharing of dossiers and assessment
reports lead to a lag time.

•

Capacity and Capabilities of EAC NMRA to
Conduct Scientific Review of Medicinal
Product Dossiers: limited capacity and
capability of some NMRA to conduct timely
scientific review of quality, safety and
efficacy data contribute to delay in
submission of assessment reports

•

Quality of Dossiers Submitted by Applicants:
Low quality of dossier submissions by
applicants increase screening time due to
rounds of correspondence between Lead
NMRA and applicant.

•

Submission of Queries by Applicants: Delay
in response to queries by applicants
contribute significantly to lengthy joint review
process

•

Scientific Advice to Applicants: The initiative
did not provide scientific advice to applicants
to improve the quality of dossier submission
which ultimately will address lengthy
screening process.

Apart from steady progress in adhering to set
timelines for the joint review processes, EAC region
registered other key milestones in which some are
part of initial project targets (Appendix 1) and others
were part of program expansion phase. The key
milestones
included:
a) Harmonization oftechnical guidelines
and procedures:
• EAC guideline for variations of registered
vaccines and pharmaceutical products
and similar biotherapeutic products;
• EAC procedure for Active Pharmaceutical
Ingredient Drug Master File (APIDMF);
• EAC procedure for recognition of GMP
decisions of other NMRA.
b)

Regional institutions
strengthened:

established

and

• Establishment of two semi-autonomous
National Medicines Regulatory Authorities
(NMRA) (i.e. Zanzibar Food and Drugs
Agency [ZFDA] in 2017 and Rwanda Food
and Drugs Authority [Rwanda FDA];
• Four EAC NMRA were ISO 9001: 2015
certified namely Tanzania Medicines and
Medical Devices (TMDA), Zanzibar Food
and Drugs Agency (ZFDA), Pharmacy and
Poisons Board (PPB) and National Drug
Authority (NDA);
• One EAC NMRA attained the World Health
Organization (WHO) Maturity Level 3 (ML3)
i.e. Tanzania Medicines and Medical
Devices [TMDA].
c)

Expansion of the program to include other
regulatory
functions
such
as
Pharmacovigilance and Post Market
Surveillance System Strengthening; and
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•

Regional Fee for Joint Regulatory Activities
and Central Mechanism for Collection of
Fee: The region did not yet establish
harmonized fee structure for joint regulatory
activities. Lack of regional fee and
mechanism for central collection of fee lead
to administrative burden to the applicant and
consequently limit the applicant to place their
products in the market of all EAC NMRA.

..

5. CONCLUSION
This study examined for the first time the joint
regulatory process timelines for the EAC-MRH
program. A clock-stop system was implemented,
which provides data to measure performance of the
system. However, the metric tools should be
consistently updated to ensure data completeness.
Automation of the metric tool is also key to ensure
easy accessibility and timely data entry by NMRA
and EAC Secretariat. Additionally, establishment of
EAC integrated information management system
would serve as a backup mechanism to track
timelines of the joint regulatory process.
The findings (2015-2019) demonstrate substantial
improvement in total median time for joint regulatory
review process (53 to 102 working days) and
marketing authorization by NMRAs (174 to 39
working days). This improvement indicates that the
EAC-MRH initiative has potential to continue to
improve regulatory efficiency in the region and
subsequently improves patient access to new,
innovative, safe, efficacious and quality medicines.
As EACregion moves towards implementation of
joint regulatory review process for variations,
biosimilars and Active Pharmaceutical Ingredient
Drug Master File (APIDMF) system, it is crucial to
establish strategic engagement and collaboration
with
pharmaceutical
industry
stakeholders.
Additionally, there is a need to introduce a feedback
and scientific advice mechanism for pharmaceutical
industry stakeholders to improve future submissions.
Efforts should be made by the initiative to put a
regional fee structure and central fee collection
mechanism in place to reduce the administrative
burden to the applicants and ensure sustainability of
the EAC-MRH program.

5.

RECOMMENDATIONS FOR NEXT STEPS
a) The EAC region should establish an
integrated information management system
(IMS) to facilitate timely sharing of dossiers
and assessment reports.
b) The EAC needs to automate EAC metric
tools to capture regulatory timelines and
ensure consistency in data entry.
c) The EAC should establish strategic
engagement and collaboration with industry
stakeholders and feedback mechanism to
address the quality of dossier to improve
future submissions and decrease frequency
of deficiency questions and, subsequently,
shorten the time required for joint review.
d) Industry stakeholders are encouraged to
take advantage of a two-year window period
following
a
positive
regional
recommendation to place their products in all
Partner States market by payment of
applicable fees to all EAC NMRA. This will
facilitate
availability
of
high-quality
medicines for the entire region.
e) EAC fee structure and a mechanism for
central collection of fees should be explored
to reduce administrative burden to
applicants.
f)

EAC should strengthen less resourced
NMRA’s capacity on regulatory sciences to
ensure timely scientific review and
submission of assessment reports.

g) Conduct further research studies to :
•

evaluate regulatory timelines for joint
GMP inspections;

•

assess uptake of the initiative between
domestic
and
multinational
pharmaceutical manufacturers;
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•

6.

compare system performance efficiency
with other/similar international and
continental initiatives.
REFERENCES

(BCG), B. C. G. (2017). End Term Evaluation
Report of EAC Medicines Regulatory
Harmonization Program. Retrieved from
EAC SECRETARIAT, Arusha, Tanzania:
Ahonkhai, V., Martins, S. F., Portet, A., Lumpkin,
M., & Hartman, D. (2016). Speeding Access
to Vaccines and Medicines in Low- and
Middle-Income Countries: A Case for
Change and a Framework for Optimized
Product Market Authorization. PloS one.,
11(11), e0166515.
doi:10.1371/journal.pone.0166515
Al-Rubaie, M. H., Walker, S. R., & Salek, S. S.
(2014). Evaluation of the Gulf Cooperation
Council Centralized Procedure: The Way
Forward. Therapeutic Innovation &
Regulatory Science, 48(6), 709-716.
doi:10.1177/2168479014529572
Andrea, K., Joey, G., Sam, S., & Stuart, W. (2018).
The Regulatory Review Process in South
Africa: Challenges and Opportunities for a
New Improved System. Therapeutic
Innovation & Regulatory Science, 52(4),
449-458.
Dansie, L. S., Odoch, W. D., & Årdal, C. (2019).
Industrial perceptions of medicines
regulatory harmonization in the East African
Community. PLoS One, 14(6), e0218617.
doi:10.1371/journal.pone.0218617
EAC. (2000). The Treaty for the Establishment of
the East African Community. Arusha,
Tanzania
EAC. (2018). Compendium of Good Manufacturing
Practices (GMP) Technical Documents For
Harmonization of Medicines Regulation In
East African Community (EAC/TFMED/GMP/FD/COM/N2R1). In E. F. GMP
(Ed.), (pp. 356). Arusha, Tanzania.
EAC. (2019a). Compendium of Guidleines for
Medicines Evaluation and Registration for
Medicines Regulatory Harmonization in
East African Community ( EAC/TFMED/MER/FD/COM/N1R1). In EAC (Ed.),
2nd Edition (Vol. 2, pp. 187). Arusha,
Tanzania: EAC Secretariat.
EAC. (2019b). EAC Compendium of Harmonized
Guidelines for Safety and Vigilance of
Medical Products and Health Technologies.
In E. Secretariat (Ed.), (First Edition ed.,
Vol. 1, pp. 173). 2019: EAC Secretariat.

EAC, S. (2010). Project Document: East African
Community Medicines Regulatory
Harmonization Programme. ARUSHA,
TANZANIA
EWG, E., & Registration, M. E. a. (March 2020). 4th
Expression of Interest for Submission of
Application for Marketing Authorization of
Medicinal Products [Press release]
Hiiti, S., Aggrey, A., Samvel, A., Chimwemwe, C.,
Joseph, K., Murray, L., . . . David, M.
(2020). Coming Together to Improve
Access to Medicines: The Genesis of the
East African Community's Medicines
Regulatory Harmonization Initiative. (2).
Jane, M., Vincent, A., Noel, A., Aggrey, A., Samvel,
A., & Dan, H. (2020). Eight Years of the
East African Medicines Regulatory
Harmonization Initiative:Implementation,
Progress and Lessons Learned. (3).
Margareth, S., Gugu, M., Margaret, A., & Emer, C.
(2020). A New Approach to an Old
Problem: Overview of the East African
Community Medicines Regulatory
Harmonization Initiative. (1).
Ndomondo-Sigonda, M., & Ambali, A. (2011). The
African medicines regulatory harmonization
initiative: rationale and benefits. Clin
Pharmacol Ther, 89(2), 176-178.
doi:10.1038/clpt.2010.299
Ndomondo-Sigonda, M., Miot, J., Naidoo, S.,
Dodoo, A., & Kaale, E. (2017). Medicines
Regulation in Africa: Current State and
Opportunities. Pharmaceut Med, 31(6),
383-397. doi:10.1007/s40290-017-0210-x
Pierre, L. L. (2014). International Cooperation,
Convergence and Harmonization of
Pharmaceutical Regulations: Elservier Inc.
RTO's, & Secretariat, E. (2018a). Metric Tool to
Track Timelines for EAC Joint Assessment
and Registration Procedure.
RTO's, & Secretariat, E. (2018b). Metric Tool to
Track Timelines for EAC Joint GMP
Inspections.
TMDA. (2015). Register of Medicinal Products
Submitted for EAC Joint Assessment and
Registration Procedure. Tanzania: EAC
Wondiyfraw, W., John, G., Matthias, S., & Lembit,
R. (2012). Deficiencies in Generic Product
Dossiers as Submitted to the WHO
Prequalification of Medicines Programme.
Journal of Generic Medicines, 9(2), 63-74.
7. ACKNOWLEDGEMENTS
I would like to thank all of the BIRS guest faculty from
global industry and regulatory organizations for
generously sharing their professional expertise and

18
providing donated, in-kind time towards building the
professional skills and technical capabilities of the
students within the BIRS program. I would also like
to thank my fellow peers in the BIRS MS student
cohort for providing guidance and constructive
feedback during the classroom group work and
interactive sessions; Abigail Ekeigwe and Mercy
Okezue, Purdue ABE BIRS PhD candidates, for their
mentorship and input throughout the project;
Professor Fran Eckenrode for providing content
expertise throughout the review process on this
paper; and Lauren Terruso, operations manager for
BIRS Center, for all of her efforts on editing multiple
iterations of the technical paper draft in preparation
for publication. The international component of the
Purdue BIRS program was initiated through
educational support provided by the Merck

Foundation and most recently through a capacity
building effort funded by the Bill and Melinda Gates
foundation, grant # 41000460.
I would also like to extend appreciation to all EAC
NMRA for collaboration to strengthen regulatory
systems and advance harmonization agenda in the
East Africa region.
Lastly, I wish to thank Tanzania Medicines and
Medical Devices Authority and EAC Secretariat for
championing development of metric tools to
document and track registration timelines for medical
products. The metric tools provided data that were
used to inform analysis of this study.

19
Appendix 1
Table 1
EAC-MRH Programme Critical Milestones and Indicators of Success
Objective

Critical Milestones

Indicators of Success

1

EAC CTD implemented in at least Eighteen (18) Medicines approved under joint assessment scheme by end of year 5
3 Partner States by end of year 3
and in all EAC Partner States by
end of year 5

2

A common integrated IMS NMRAs and 1 regional websites regularly updated
established and linked in all
Partner
States
and
EAC Centralized Portal to share information and work established
Secretariat by end of year 4

3

Quality management system Three (3) NMRAs ISO certified by the end of year 3
implemented in each of the EAC
Partner States NMRAs by end of
year 3

4

Institutional,
human
and Two (2) regional centre’s of excellence in training assessors and GMP inspectors
infrastructural capacity built by established in the EAC region by the end of year 5
end of year 5
25 NMRAs and EAC Secretariat staff trained on project management
Regulatory capacity building
programs institutionalized into 24 assessors trained in assessment of quality, safety and efficacy of medicines by the end
existing structures in Partner of year 5
States NMRAs by the end of year 24 inspectors trained on GMP inspection by end of year 5
5
Regional capacity to coordinate
the
medicines
registration
harmonization strengthened by
the end of year 5

5

Government commitment to Rwanda and Burundi semi-autonomous NMRAs established by end of year 5
EAC-RH Programme secured by
100 applications submitted to NMRAs as per EAC CTD
end of year 5
Industry-buy in and commitment Partner States commitment to fund EAC-MRH programme
to EAC-MRH program secured
by the end of year 5

Public awareness on EAC-RH
created by end of year 5
6

A framework
for
mutual Seven (7) NMRAs recognizing regulatory decisions made by other NMRAs based on
recognition
of
regulatory mutual recognition framework by end of year 5
decisions made by other EAC
Partner States NMRAs developed
and implemented by end of year 5
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Appendix 2:
Table 2
Summary of Product Registration Timelines (Submission to End of Assessment) for Regulator and Applicant

Product Number

Year

Product Category

Type of Assessment

Regulator
Timelines

Applicant
Timelines

001

2015

Antineoplastic

Abridged

53

0

002

2015

Antineoplastic

Abridged

53

0

003

2015

Antineoplastic

Abridged

53

0

004

2015

Antineoplastic

Abridged

53

0

005

2015

Antihypertensive

Full

125

927

006

2015

Antihypertensive

Full

125

927

007

2015

Antihypertensive

Full

125

927

008

2016

Antineoplastic

-

96

30

009

2016

Antineoplastic

-

-

-

010

2016

Antidiabetic

Full

327

419

011

2016

Antidiabetic

Full

327

419

012

2016

Antihypertensive

Full

327

419

013

2016

Antihypertensive

Full

327

419

014

2016

Antituberculosis

Abridged

141

27

015

2016

Antihypertensive

-

289

141

016

2016

Antihypertensive

-

289

141

017

2016

Antihypertensive

-

289

141

018

2016

Antineoplastic

-

391

294

019

2016

-

-

-

-

21

020

2016

021

2016

022

-

-

-

-

Antihypertensive

-

266

380

2016

Antihypertensive

-

266

380

023

2016

Antineoplastic

-

153

42

024

2016

Antipyretic

-

267

194

025

2016

Antiseptic

-

343

180

026

2016

Antibiotic

-

104

65

027

2017

Antifungal

-

169

119

028

2017

Antifungal

-

169

119

029

2017

Mineral
Supplements

-

381

43

030

2017

Antiseptic

-

180

412

031

2017

Antineoplastic

-

207

95

032

2017

Antineoplastic

-

135

0

033

2017

Antineoplastic

-

135

0

034

2017

Antiretrovirals

-

101

254

035

2017

Antiallergics

-

122

88

036

2018

Antineoplastic

Abridged

73

9

037

2018

Overactive
Bladder

-

174

47

038

2018

Overactive
Bladder

-

174

47

039

2018

Antibiotic

Abridged

87

74

040

2018

Antiretroviral

Full

166

35

041

2019

Antineoplastic

Full

63

0

042

2019

Antineoplastic

Full

63

0

043

2019

Antineoplastic/Bio
logical

Full

85

0

044

2019

Antineoplastic/Bio
logical

Full

85

0

22

045

2019

Monoclonal
Antibodies

Abridged

046

2019

Monoclonal
Antibodies

Abridged

047

2019

Monoclonal
Antibodies

Abridged

048

2019

Monoclonal
Antibodies

Abridged

049

2019

Gynaecological
Anti-infective

Abridged

050

2019

Antivertigo

051

2019

Antineoplastic

052

2019

Emergence
Allergic Reaction

Full

053

2019

Nerve Agent &
Insecticide
Poisoning

Full

054

2019

Treatment of
Asthma

Full

055

2019

Treatment of Male
Impotence

Full

056

2019

Treatment of Male
Impotence

Full

057

2019

Treatment of Male
Impotence

Full

222

0

222

0

222

0

222

0

229

0

Full

44

0

Abridged

85

0

-

-

-

-

-

-

102

51

102

51

102

51

23
Appendix 3
Table 3
Registration Timelines at National Level (Marketing Authorisation) for Each EAC National Medicines Regulatory Authorities
Product
Number

Year
Marketing Authorisation Timelines (Working Days)
PPB

NDA

TM
DA

Rwan
da
FDA

DPL
M

ZFDA

DFC
A

001

2015

0

150

0

PR

NS

NS

NS

002

2015

0

150

30

PR

NS

NS

NS

003

2015

0

150

0

PR

NS

NS

NS

004

2015

0

150

30

PR

NS

NS

NS

005

2015

NS

43

24

NS

NS

NS

NS

006

2015

NS

43

24

NS

NS

NS

NS

007

2015

NS

43

24

NS

NS

NS

NS

008

2016

0

594

307

PR

NS

NS

NS

009

2016

0

47

1

NS

NS

NS

NS

010

2016

0

1

53

NS

NS

NS

NS

011

2016

0

1

53

NS

NS

NS

NS

012

2016

0

NS

53

NS

NS

NS

NS

013

2016

0

NS

53

NS

NS

NS

NS

014

2016

ND

NS

272

PR

NS

NS

NS

015

2016

0

NS

53

NS

NS

NS

NS

016

2016

0

NS

53

WA

NS

NS

NS

017

2016

0

0

53

NS

NS

NS

NS

018

2016

ND

0

53

NS

NS

NS

NS

019

2016

0

NS

25

NS

NS

NS

NS

020

2016

0

NS

25

NS

NS

NS

NS

24

021

2016

0

0

53

NS

NS

NS

NS

022

2016

0

0

53

NS

NS

NS

NS

023

2016

ND

340

108

NS

NS

NS

NS

024

2016

0

0

0

NS

NS

NS

NS

025

2016

0

NS

40

NS

NS

NS

NS

026

2016

0

498

83

NS

NS

NS

NS

027

2017

0

NS

49

NS

NS

NS

NS

028

2017

0

NS

49

NS

NS

NS

NS

029

2017

0

NS

40

NS

NS

NS

NS

030

2017

ND

NS

33

NS

NS

NS

NS

031

2017

0

0

48

PR

NS

NS

NS

032

2017

0

116

49

NS

NS

NS

NS

033

2017

0

116

49

NS

NS

NS

NS

034

2017

ND

0

27

NS

NS

NS

NS

035

2017

ND

NS

70

NS

NS

PR

NS

036

2018

51

NS

48

NS

NS

NS

NS

037

2018

51

NS

48

NS

NS

NS

NS

038

2018

ND

0*

1

WA

NS

NS

NS

039

2018

128

NS

27

NS

NS

NS

NS

040

2018

ND

NS

79

NS

NS

NS

NS

041

2019

ND

NS

155

NS

NS

NS

NS

042

2019

ND

NS

5

NS

NS

NS

NS

043

2019

ND

NS

5

NS

NS

NS

NS

044

2019

0

NS

79

NS

NS

NS

NS

045

2019

NS

NS

5

NS

NS

NS

NS

046

2019

NS

NS

5

NS

NS

NS

NS

047

2019

34

NS

0*

NS

NS

NS

NS

25

048

2019

34

NS

0*

NS

NS

NS

NS

049

2019

34

0

0*

NS

NS

NS

NS

050

2019

34

0

0*

NS

NS

NS

NS

051

2019

ND

NS

40

NS

NS

NS

NS

052

2019

ND

NS

40

NS

NS

NS

NS

053

2019

ND

NS

40

NS

NS

NS

NS

054

2019

ND

NS

40

NS

NS

NS

NS

055

2019

ND

NS

5

NS

NS

NS

NS

056

2019

ND

NS

5

NS

NS

NS

NS

057

2019

0

WA

5

NS

NS

NS

NS

Key to Appendix 3
PPB- Pharmacy and Poisons Board, Republic of Kenya
NDA- National Drug Authority, Republic of Uganda
TMDA- Tanzania Medicines and Medical Devices Authority, United Republic of Tanzania
Rwanda FDA- Rwanda Food and Drugs Authority, Republic of Rwanda
DPML- Department of Pharmaceuticals and Medical Laboratories, Republic of Burundi
ZFDA- Zanzibar Food and Drugs Agency, United Republic of Tanzania
DFCA – Drug and Food Control Authority, Republic of South Sudan
PR- Pre-registration pending fee payment by applicant
NS- Application for marketing authorisation not submitted by applicant
ND- No Data
WA – Submitted waiting NMRA approval
Zero (0) Days- Product already registered in country before EAC joint assessment
0* Days - Product registered between 5 to 30 days before regional recommendation

